Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations that currently lack FDA-approved treatments. On December 13, 2024, the company completed a business combination with Legacy Palvella, resulting in Legacy Palvella becoming a wholly-owned subsidiary and the company changing its name from Pieris Pharmaceuticals, Inc. to Palvella Therapeutics, Inc. Its business is now primarily that of Legacy Palvella. The company aims to become a leader in rare disease biopharmaceuticals by providing improved treatment options that address the underlying causes of these conditions. Palvella leverages its QTORIN platform, designed to generate novel topical product candidates that penetrate deep skin layers for local treatment of a broad range of rare skin diseases and vascular malformations. The company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations.